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1 These authors contributed equally to this work.The adaptor protein 14-3-3 binds to and stabilizes the tumor suppressor p53 and enhances its anti-
tumour activity. In the regulatory C-terminal domain of p53 several 14-3-3 bindingmotifs have been
identiﬁed. Here, we report the crystal structure of the extreme C-terminus (residues 385–393,
p53pT387) of p53 in complex with 14-3-3r at a resolution of 1.28 Å. p53pT387 is accommodated
by 14-3-3 in a yet unrecognized fashion implying a rationale for 14-3-3 binding to the active p53 tet-
ramer. The structure exhibits a potential binding site for small molecules that could stabilize the
p53/14-3-3 protein complex suggesting the possibility for therapeutic intervention.
Structured summary:
MINT-7711943: 14-3-3 sigma (uniprotkb:P31947) and p53 (uniprotkb:P04637) bind (MI:0407) by X-ray
crystallography (MI:0114)
MINT-7711931: 14-3-3 sigma (uniprotkb:P31947) and p53 (uniprotkb:P04637) bind (MI:0407) by isother-
mal titration calorimetry (MI:0065)
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The tumour suppressor protein p53 plays a decisive role in cell
cycle arrest and apoptosis and is frequently mutated in human
cancers [1]. p53 is a homotetrameric transcription factor with each
monomer of 393 residues displaying six distinct domains (Fig. 1a)
[2]. A multitude of post-translational modiﬁcations has been re-
ported that activate p53, among them phosphorylations of the N-
and the C-terminus [3]. The major negative regulator of p53 is
MDM2, an E3 ubiquitin ligase targeting p53 for proteasomal degra-
dation [4].
The 14-3-3 proteins are a class of adapter proteins with seven
isoforms (b, c, e, g, r, s, and f) in humans. They have been found
to bind to the regulatory C-terminal domain of p53, stabilizing the
tumour suppressor and enhancing its biological activity [5,6,25].
Several crystal structures of 14-3-3 proteins in complex with short
(4–10 residues) phosphopeptides [7–9], a slightly longer (14 resi-
dues), unphosphorylated binding motif [10], a 52-residue, dimeric
interaction domain [11] and a nearly full-length partner with 200
residues [12] have been reported. As demonstrated by these struc-
tures, binding to 14-3-3 employs different peptide motifs (Fig. 2cchemical Societies. Published by E
9.
Ottmann).and d) and association of p53 and 14-3-3 displays some formerly
not described features of 14-3-3/phosphopeptide interactions.
The initial report of the interaction of 14-3-3 with p53 involved
phosphorylation of S378 in p53 with 14-3-3 association leading to
enhanced promoter activity of p53 [5]. Furthermore, it was shown
that 14-3-3 binding to p53 protects the tumour suppressor from
MDM2-dependent degradation and stabilized the tetrameric oligo-
merization state [6], characterizing 14-3-3 as a positive regulator
of p53 activity. Recently, in addition to S378, phosphorylated
T387 has been reported to promote the binding of 14-3-3 [13].
We elucidated the structure of the complex with the motif sur-
rounding pT387 bound to 14-3-3r. The resulting structure can
be combined with the tetrameric model of p53 bound to DNA
[14] providing a rationale for the observed stabilizing effect of
14-3-3 binding. Furthermore, the structure reveals a pocket with
the potential for accommodating a small, protein–protein stabiliz-
ing molecule. Such a molecule could enhance the p53 activating ef-
fect that results from binding to 14-3-3 proteins.
2. Materials and methods
2.1. Protein puriﬁcation
Puriﬁcation of His6-tagged 14-3-3r protein was carried out
using standard procedures. The protein was dialyzed against 20
mM Hepes/NaOH pH 7.5, 100 mM NaCl, 10 mM MgCl2 andlsevier B.V. All rights reserved.
Fig. 1. Binding of the p53pT387 peptide to 14-3-3r. (a) Domain Structure of p53 with post-translational modiﬁcation of the C-terminal domain (CTD). TAD = transcriptional
activation domain, PD = proline domain, L = linker region, TetD = tetramerization domain, Ac = acetylation, P = phosphorylation, Ub = ubiquitination, S = sumoylation. (b)
Isothermal titration calorimetry of 14-3-3r titrated with the p53pT387 peptide. Top panels, raw heating power over time; bottom panels, ﬁt of the integrated energy values
normalized for injected peptides. (c) Ribbon plot of the 14-3-3r dimer (blue) complexed with the p53pT387 peptide (yellow sticks, rainbow ribbon).
1444 B. Schumacher et al. / FEBS Letters 584 (2010) 1443–14480.5 mM TCEP and stored at 80 C. The phosphopeptide was syn-
thesized by Biosyntan (Berlin, Germany).
2.2. Crystallization
For crystallization of the 14-3-3r/p53pT387 peptide complex,
protein and peptides were mixed in 1:1.5 molar ratio in 20 mM
Hepes/NaOH pH 7.5, 2 mM MgCl2 and 2 mM DTT and set up for
crystallization in 0.1 M Hepes/NaOH pH 7.5, 0.2 M CaCl2, 28%
PEG 400, 5% glycerol, 2 mM DTT at 4 C. Crystals grew within a
week and could directly be ﬂash-cooled in liquid nitrogen.
2.3. Data collection, structure determination and reﬁnement
Data collection was performed at the Swiss Light Source, and
was processed with XDS [15]. Molecular replacement was carried
out with PHASER [16] with the structure of 14-3-3r (PDB code
1YWT) used as the search model. The obtained model was sub-
jected to iterative rounds of model building and reﬁnement using
the programs COOT [17] and REFMAC [18]. Figures were prepared
with PYMOL (www.pymol.org).
2.4. Isothermal titration calorimetry (ITC)
Experiments were carried out in buffer containing 20 mM MES
pH 6.5 with 2 mM MgCl2 at 15 C. In the sample cell, a solution of
50 lM 14-3-3 protein was placed and titrated stepwise with 6 ll
aliquots of a 500 lM solution of p53pT387. The association con-
stant Ka (Ka = 1/Kd), molar binding stoichiometry (N), and the molar
binding enthalpy (DH) were determined by ﬁtting the binding iso-
therm by a single binding site model. The listed Kd value is the
average of three independent measurements.3. Results and discussion
3.1. Binding of the p53pT387 peptide to 14-3-3
ITC measurement was used to quantify the afﬁnity of the pT387
region (385FKpTEGPDSD393-COOH) of the p53 C-terminus to 14-3-
3r. The phosphorylated peptide p53pT387 binds with a Kd of
16.3 ± 0.7 lM (Fig. 1B). This value ﬁts nicely with the value
recently reported by others [13], who measured the binding of a
similar peptide to 14-3-3c (Kd = 14 ± 3 lM) and 14-3-3e (Kd =
11 ± 2 lM) using ﬂuorescence anisotropy titration. Our Kd deter-
mined by ITC is similar to those of previously reported 14-3-3/
phosphopeptide interactions when dissociation constants were ob-
tained with the same method [8,19]. As expected, the stoichiome-
try from our ITC experiments indicates that two phosphopeptides
bind to one 14-3-3 dimer.
3.2. Structure of the 14-3-3/p53pT387 complex
To elucidate the structural basis of the p53/14-3-3 interaction in
atomic detail, we solved the crystal structure of 14-3-3r in
complex with the p53pT387 peptide to 1.28 Å by molecular
replacement (start model: 1YWT). For the 14-3-3r protein we
found interpretable density for 230 out of 231 residues. For the
p53pT387 peptide the ﬁnal density allowed building of 7
(385FKpTEGPD391) out of 9 residues. Data and reﬁnement statistics
are summarized in Supplementary Table 1. The 14-3-3 dimer
displays the characteristicW-like shapewith each of themonomers
harbouring one p53pT387 peptide (Fig. 1c). In accordance with pre-
viously solved 14-3-3/phosphopeptide structures the p53pT387
peptide is bound in an extended conformation and is coordinated
predominantly by electrostatic interactions (Fig. 2a and b).
Fig. 2. Structure of the p53pT387/14-3-3r complex. (a) Electrostatic interactions (dotted lines) between residues from 14-3-3r (blue) and p53pT387 (yellow). (b) 2FO  FC
electron density map of p53pT387 (yellow sticks) and selected waters (red spheres) contoured at 1r is shown in black. (c) Comparison of the primary sequence of different
14-3-3 interaction motifs. Phosphorylation sites and amino acids important for directing the peptide backbone are highlighted. (d) Superimposition of p53pT387 and
different 14-3-3 interaction motifs bound to 14-3-3, corresponding PDB codes are shown in parentheses.
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14-3-3 proteins have initially been described as adapter pro-
teins that recognize their partner proteins by either a mode 1
(RSXpSXP) or a mode 2 motif (RXF/YXpSXP) [20,21]. Since then,
several additional interaction motifs have been reported, among
them a so-called mode 3 motif that ends C-terminally from the
phosphorylated serine/threonine [22], as well as the histone H3
[9] and beta2 integrin [10] speciﬁc motifs. Although all these mo-
tifs contain a central phosphorylated amino acid, they employ dif-
ferent residues at different positions to exit the central binding
channel of the 14-3-3 proteins. The mode 1 and 2 motifs display
an invariant proline at position +2 from the phosphorylated amino
acid that redirects the peptide backbone (Fig. 2c and d). Deviating
strongly from this arrangement, in the 14-3-3 interaction motif
from beta2 integrin a threonine is found at the +2 position which
preserves the direction of the peptide backbone. Interestingly,
the main-chain nitrogen of the +2 threonine (T760) in beta2 inte-
grin overlays nicely (R.M.S.D. = 0.61 Å) with that of the +2 glycine
(G389) in p53 (Fig. 2d). In the histone H3 interaction motif two
consecutive glycines at positions +2 and +3 are leading the peptideaway from the primary phospho-acceptor site. In p53 the +2 resi-
due is also a glycine (G389) introducing a kink in the polypeptide
backbone, but it is followed by a proline (P390) thus creating a
rather unique 14-3-3 interaction which is further characterized
by the fact, that the polypeptide chain ends at the +5 position
(D393, Fig. 1a). Thus, in contrast to most other 14-3-3 protein part-
ners with interaction motifs located rather at the N-terminus or in
the middle of the protein like Raf1 (S259, S621 of 648 residues) or
Cdc25C (S216 of 473 residues), the polypeptide of p53 is neither
expected to exit the 14-3-3 binding groove nor to occupy further
space in the 14-3-3 channel. This has important consequences
for the possible modulation of the p53/14-3-3 interaction by small
molecules addressing the interface of the proteins.
3.4. Role of 14-3-3 for the p53 tetramer
Full-length p53 has eluded structural elucidation by X-ray crys-
tallography so far. Nevertheless, the structures of the p53 DNA-
binding domain [23] and the tetramerization domain [24] have
been solved by X-ray crystallography or NMR and were ﬁtted into
the EM volume of full-length p53 in complex with a 60-bp dsDNA
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merization domain approximately 40 Å apart, connected by the
unstructured linker region. The four C-termini exit the tetramer
as pairs of two in opposite directions. Based on this model, we de-
pict a possible constellation of how two 14-3-3 dimers could bind
to the p53 tetramer (Fig. 3 and Supplementary data S1). This hypo-
thetical model ﬁts well to the results that binding of 14-3-3 pro-
teins shift the equilibrium of p53 oligomerization to the active
tetrameric form resulting in an enhanced afﬁnity for target promo-
tors [5,13]. This very mechanism has recently been shown by the
group of Fersht [25]. Furthermore 14-3-3 binding in our model
masks parts of the regulatory C-terminal domain that otherwise
is prone to ubiquitination leading to proteasomal degradation ofFig. 3. Model of the DNA-bound p53 tetramer with two C-terminally bound 14-3-3 dime
tetramerization domain as rainbow-colored ribbons and 14-3-3 as blue ribbons with the
residues connecting the 14-3-3 dimers to the C-termini of the individual p53 chains of th
70 Å.p53 [6] which is especially true for lysine K386 as shown by our
structure.
3.5. Potential stabilization of the p53/14-3-3 complex by small
molecules
We previously solved the 14-3-3 complex structures of Fusicoc-
cin and Cotylenin stabilizing a 14-3-3 protein-protein interaction
[11,19,26]. A prerequisite for binding of these molecules is the
accessibility of a conserved pocket in the interface of the 14-3-3/
partner protein complex. In the majority of 14-3-3 complexes this
pocket is partially occupied by residues of the 14-3-3 target pro-
tein. However, in our 14-3-3/p53pT387 structure a pocket for ars. The DNA-binding domain is shown as green ribbon bound to DNA (magenta), the
extreme C-terminus of p53 displayed as yellow sticks. The maximal length of the 28
e tetramerization domain is represented as transparent grey spheres with a radius of
Fig. 4. The 14-3-3r/p53pT387 interface displays a potential drug-binding pocket. (a) A potential drug-binding pocket identiﬁed with SCREEN is established at the interface of
14-3-3r (marine ribbon) and p53pT387 (yellow sticks). The surface of this pocket is formed by both the 14-3-3 protein (red surface) and the phosphopeptide derived from
the regulatory C-terminus of p53 (green surface). (b) Example of two molecules from a virtual screening, ZINC19931902 and ZINC04879460 (c), binding to the identiﬁed
pocket.
Fig. 5. Possible effect of a small molecule stabilizing the p53/14-3-3 protein-protein interaction. (a) p53 is subject to rapid degradation that counteracts its tumour
suppressor activity. (b) Binding of 14-3-3 proteins leads to stabilization of the p53 tetramer, protection against MDM2-mediated degradation and increases its tumour
suppressor activity. These effects might be enhanced with small molecules that stabilize the binding of 14-3-3 to the C-terminus of p53.
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this binding site also exists in the 14-3-3 complex with full-length
p53. Fusicoccin itself cannot bind to the 14-3-3/p53pT387 complex
due to sterical and electrostatic incompatibility of p53 E388 and
Fusicoccin (Supplementary Fig. S1). However, other molecules
binding to this site and contacting both protein partners simulta-
neously might be interesting compounds to modulate p53 activity
in a yet unexplored way with the potential of a therapeutic beneﬁtin cancers with deregulated p53 activity (Fig. 4). To gain informa-
tion on drug-binding ability of this complex we analysed it using
the method SCREEN for prediction of potential drug-binding cavi-
ties [27]. Fig. 5a shows the prediction of a cavity at the site of inter-
est. The geometric and physicochemical parameters are in the
same range of known drug-binding pockets (see Supplementary
Table S2). Using this information we performed a virtual screening
of 10 000 small molecules onto the predicted binding pocket
1448 B. Schumacher et al. / FEBS Letters 584 (2010) 1443–1448(Fig. 5a and b, Supplementary Fig. S3). Both, the pocket analysis
and the predicted binding modes of numerous compounds encour-
age further exploration of this strategy.
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